#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal squamous cell carcinoma Hepatocellular carcinoma Fibrodysplasia ossificans progressiva Mucopolysaccharidosis II Chronic myeloid leukaemia (in remission) Gastrointestinal neuroendocrine tumour Rheumatoid arthritis Cardiac arrest Microvillous inclusion disease Acute lymphocytic leukaemia recurrent Ocular myasthenia Scedosporium infection Lymphangiosarcoma Aspergillus infection Choroidal dystrophy More trials…

    Learn about Rare Diseases

    Richter’s syndrome – Diagnostics Adrenocortical carcinoma – Life with Disease Nodal marginal zone B-cell lymphoma – Life with Disease Marfan’s syndrome – Treatment KBG syndrome – Basic Information Pituitary-dependent Cushing’s syndrome – Trials in Disease Retinoblastoma – Treatment Waldenstrom’s macroglobulinaemia refractory – Diagnostics Leiomyosarcoma recurrent – Basic Information Rett syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LIPASE Pralatrexate Eptacog Beta (Activated) Garadacimab Tuvusertib Gandotinib Poa Pratensis Rbl035.2 Padeliporfin Pomalidomide Tofogliflozin Emapalumab Levoleucovorin Disodium Gemlapodect Dopamine Hydrochloride Seladelpar (-)-PHENSERINE TARTRATE Pentixather Nanatinostat Other Blood Products More therapies…

    Learn about Your Condition

    Hypertrophic scar Fibromyalgia Bronchitis Neurodevelopmental disorder Muscle injury Skin papilloma Choroidal dystrophy Sexual dysfunction Radicular pain Alveolar rhabdomyosarcoma Hypotonia Angiosarcoma recurrent Chondropathy Cough Retroperitoneal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Jagiellońskie Centrum Innowacji Sp. z o.o.

Jagiellońskie Centrum Innowacji Sp. z o.o.

Ul. Profesora Michala Bobrzynskiego 14, Cracow, 30-348, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil Hydrochloride
    • Trifluridine
    Austria Belgium Denmark France Germany Italy +3

  • Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

    Recruiting

    3 1
    Investigated Diseases:
    • Chronic cutaneous lupus erythematosus
    • Cutaneous lupus erythematosus
    • Subacute cutaneous lupus erythematosus
    Belgium Bulgaria France Germany Greece Italy +4

  • A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

    Recruiting

    4 1
    Investigated Diseases:
    • Cachexia
    Investigated Drugs:
    • VISUGROMAB
    Bulgaria Czechia France Germany Ireland Italy +5

  • A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST PD-L1 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A VALINE-CITRULLINE LINKER
    • Docetaxel
    Belgium Bulgaria Czechia Denmark Finland France +8

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Glatiramer Acetate
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark France Germany +6

  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Bulgaria Czechia Denmark Finland France Germany +8

  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Azenosertib
    • Granisetron
    • Betamethasone Sodium Phosphate Ph. Eur
    Belgium France Italy Poland Spain

  • Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cervix carcinoma
    Investigated Drugs:
    • Infliximab
    • Mycophenolate Mofetil
    • Volrustomig
    Denmark Germany Italy Norway Poland Spain

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!